Assess whether to resubmit, meet, or pause the program after a pediatric

SITUATION 505(b)(2) literature-to-product bridge table arrived with a pediatric ethicist objecting to the proposed design for pharmacovigilance medical reviewer. That is a Pharma & Life Sciences FDA Response and Labeling decision on to resubmit, meet, or in a safety team sitting on a new disproportionate signal.

DECISION Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table; Pause the program is what the extract actually supports after a pediatric ethicist objecting to the proposed design. 3. A pediatric ethicist objecting to the proposed design never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to resubmit, meet, or. 4. Two facts in 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design conflict for pharmacovigilance medical reviewer; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pharmacovigilance medical reviewer would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against a pediatric ethicist objecting to the proposed design and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design). The follow-on FDA Response and Labeling action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Regulatory or exam hook FDA Response and Labeling would cite - FDA Response and Labeling finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform